VistaGen Therapeutics, Inc. (VTGN) Stock Forecast
VTGN analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.00 / 5 from 4 analysts
- Price target
- $1.00 average of analyst targets
- Upside to target
- +400.0% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.37
- 52-week range
- $0.20 – $4.90
VTGN analyst ratings
4 analystsNumber of analysts at each rating.
VTGN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VTGN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.38 | −$0.37 | −$0.54 | +30.6% | 2 |
| Next quarter (Dec '26) | −$0.36 | −$0.37 | −$0.36 | −$0.45 | +18.9% | 2 |
| Current fiscal year (FY2027) | −$1.48 | −$1.50 | −$1.45 | −$1.83 | +19.4% | 2 |
| Next fiscal year (FY2028) | −$1.54 | −$1.54 | −$1.54 | −$1.48 | −4.4% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VTGN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $250,000 | $0 | $500,000 | −3.1% | 2 |
| Next quarter (Dec '26) | $250,000 | $0 | $500,000 | −17.5% | 2 |
| Current fiscal year (FY2027) | $1.7M | $1.5M | $1.9M | +34.0% | 2 |
| Next fiscal year (FY2028) | $0 | $0 | $0 | −100.0% | 1 |
VTGN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VTGN revenue: reported and forecast
VTGN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.38 | −$0.38 | −$0.37 | −$0.37 | −$0.38 | 0.0% | 0 up · 2 down |
| Next quarter (Dec '26) | −$0.36 | −$0.36 | −$0.36 | −$0.36 | −$0.36 | 0.0% | 0 up · 2 down |
| Current fiscal year (FY2027) | −$1.48 | −$1.48 | −$1.45 | −$1.45 | −$1.48 | 0.0% | 0 up · 2 down |
| Next fiscal year (FY2028) | −$1.11 | −$1.54 | −$1.54 | −$1.54 | −$1.54 | +38.7% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VTGN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VTGN beat in 9 of 12.
What analysts expect from VTGN
4 analysts cover VistaGen Therapeutics; their consensus rating is hold (3.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.00, 400.0% above the latest close of $0.20. Analysts expect earnings of −$1.48 per share for FY2027, +19.4% from a year earlier. For FY2028 the average estimate is −$1.54 per share. VistaGen Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: VTGN income statement, VTGN key metrics, VTGN chart. See the VTGN stock overview for the latest quote and news.
VTGN forecast FAQ
What is VistaGen Therapeutics's price target?
The average analyst price target for VistaGen Therapeutics is $1.00, 400.0% above the latest close of $0.20.
Is VistaGen Therapeutics a buy, hold or sell?
Of 4 analysts covering VistaGen Therapeutics, 0 rate it a strong buy, 0 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is VistaGen Therapeutics's EPS forecast?
Analysts forecast −$1.48 per share for FY2027 (range −$1.50 to −$1.45); for FY2028 the estimate is −$1.54.
What is VistaGen Therapeutics's revenue forecast?
The average revenue estimate for FY2027 is $1.7 million, growth of 34.0%.
When does VistaGen Therapeutics report earnings?
VistaGen Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 before the market opens; the EPS estimate is $-0.37.
Does VistaGen Therapeutics usually beat earnings estimates?
VistaGen Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.